Thu, Sep 18, 2014, 8:30 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • johnpapas893 johnpapas893 Mar 11, 2013 10:48 AM Flag

    MS report

    March 11, 2013
    Onyx Pharmaceuticals
    A Key Endorsement
    Impact on our views: Addition of Kyprolis to National Comprehensive Cancer Network or NCCN treatment
    guidelines for newly diagnosed myeloma patients undergoing stem cell transplant is an expected positive.
    Front line use is largely upside to MSe/consensus and should allay concerns about competitive pressures from
    Celgene’s Pomalyst. Moreover, guideline inclusion will ease front line reimbursement and create an additional
    source of growth in the coming quarters.

    NCCN treatment guideline details as expected. Kyprolis is listed as an “other regimen” (versus a preferred regimen) for primary therapy in patients undergoing stem cell transplant for use in combination with Revlimid and dexamethasone. Kyprolis received a Category 2A recommendation meaning that “based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.”

    How much bigger? We estimate roughly 40-50% of the ~15,000 treated front line patients receive a stem
    cell transplant in the US. Moreover, Kyprolis should fit in with the roughly 25% of patients currently receiving the combination of the other marketed proteasome inhibitor Velcade + Revlimid and dex. The magnitude of the near term front line opportunity for Kyprolis is difficult to call. However, given broad off-label use in myeloma, (front line use of Celgene’s Revlimid for example) we expect uptake of Kyprolis to grow over time as physicians gain comfort with the regimen.

    In other news. Recently published dose escalation data from the 006 trial provide early insights in the key
    ASPIRE trial (1-3 prior lines of therapy comparing CRd to Rd). While only 8 patients, at the ASPIRE regimen of
    20/27 mg/m2 of Kyprolis and 25 mg of Revlimid, the response rate was 87.5% and the median PFS was 14.6
    months. This compares favorably to a 60% response rate and ~11 months of PFS for Revlimid and dex in the
    line 2+ MM-009/MM-010 trials. CRd looked superior despite 70% of patients being previously treated with
    Revlimid or Velcade (~55% both). We look forward to
    data from the 44 patient 006 expansion cohort at ASCO.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.